Molecular targets of glioma invasion.
Glioblastoma multiforme is the most common and lethal primary malignant brain tumor. Although considerable progress has been made in technical proficiencies of surgical and radiation treatment for brain tumor patients, the impact of these advances on clinical outcome has been disappointing, with median survival time not exceeding 15 months. Over the last 30 years, no significant increase in survival of patients suffering from this disease has been achieved. A fundamental source of the management challenge presented in glioma patients is the insidious propensity of tumor invasion into distant brain tissue. Invasive tumor cells escape surgical removal and geographically dodge lethal radiation exposure and chemotherapy. Recent improved understanding of biochemical and molecular determinants of glioma cell invasion provide valuable insight into the underlying biological features of the disease, as well as illuminating possible new therapeutic targets. These findings are moving forward to translational research and clinical trials as novel antiglioma therapies.
Nakada
M
M
Cancer and Cell Biology Division, The Translational Genomics Research Institute, 445 North Fifth Street, Phoenix, Arizona, 85004, USA.
Nakada
S
S
Demuth
T
T
Tran
N L
NL
Hoelzinger
D B
DB
Berens
M E
ME
D002986:Clinical Trials as Topic; D005109:Extracellular Matrix / Q000378:metabolism; D005910:Glioma / Q000378:metabolism* / Q000473:pathology* / Q000628:therapy; D006801:Humans; D009361:Neoplasm Invasiveness / Q000473:pathology* / Q000517:prevention & control; D009363:Neoplasm Proteins / Q000378:metabolism; D009360:Neoplastic Cells, Circulating / Q000473:pathology
D009363:Neoplasm Proteins